Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
GMED's Cash-to-Debt is ranked higher than
87% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 2.87 vs. GMED: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
GMED' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.91
GMED's Equity-to-Asset is ranked higher than
95% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. GMED: 0.91 )
Ranked among companies with meaningful Equity-to-Asset only.
GMED' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.83  Med: 0.86 Max: 0.91
Current: 0.91
0.83
0.91
Interest Coverage No Debt
GMED's Interest Coverage is ranked higher than
90% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 71.12 vs. GMED: No Debt )
Ranked among companies with meaningful Interest Coverage only.
GMED' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 5
Altman Z-Score: 21.23
Beneish M-Score: -2.42
WACC vs ROIC
8.27%
19.29%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 25.37
GMED's Operating Margin % is ranked higher than
94% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 3.05 vs. GMED: 25.37 )
Ranked among companies with meaningful Operating Margin % only.
GMED' s Operating Margin % Range Over the Past 10 Years
Min: 23.4  Med: 29.37 Max: 31.61
Current: 25.37
23.4
31.61
Net Margin % 18.12
GMED's Net Margin % is ranked higher than
89% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. GMED: 18.12 )
Ranked among companies with meaningful Net Margin % only.
GMED' s Net Margin % Range Over the Past 10 Years
Min: 15.79  Med: 18.9 Max: 20.7
Current: 18.12
15.79
20.7
ROE % 12.86
GMED's ROE % is ranked higher than
81% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.53 vs. GMED: 12.86 )
Ranked among companies with meaningful ROE % only.
GMED' s ROE % Range Over the Past 10 Years
Min: 12.86  Med: 17.42 Max: 43.04
Current: 12.86
12.86
43.04
ROA % 11.59
GMED's ROA % is ranked higher than
89% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.11 vs. GMED: 11.59 )
Ranked among companies with meaningful ROA % only.
GMED' s ROA % Range Over the Past 10 Years
Min: 11.59  Med: 14.62 Max: 36.91
Current: 11.59
11.59
36.91
ROC (Joel Greenblatt) % 55.64
GMED's ROC (Joel Greenblatt) % is ranked higher than
87% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 4.41 vs. GMED: 55.64 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GMED' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 54.7  Med: 68.29 Max: 139.86
Current: 55.64
54.7
139.86
3-Year Revenue Growth Rate 8.20
GMED's 3-Year Revenue Growth Rate is ranked higher than
61% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. GMED: 8.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GMED' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 8.2  Med: 10.65 Max: 13.5
Current: 8.2
8.2
13.5
3-Year EBITDA Growth Rate 15.90
GMED's 3-Year EBITDA Growth Rate is ranked higher than
64% of the 244 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. GMED: 15.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
GMED' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 4.5  Med: 11.1 Max: 15.9
Current: 15.9
4.5
15.9
3-Year EPS without NRI Growth Rate 13.90
GMED's 3-Year EPS without NRI Growth Rate is ranked higher than
66% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. GMED: 13.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
GMED' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 6.8  Med: 13.3 Max: 13.9
Current: 13.9
6.8
13.9
GuruFocus has detected 2 Warning Signs with Globus Medical Inc $GMED.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GMED's 30-Y Financials

Financials (Next Earnings Date: 2017-11-08)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

GMED Guru Trades in Q3 2016

Joel Greenblatt 732,178 sh (+17.88%)
Steven Cohen 300,000 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones 84,093 sh (-28.43%)
» More
Q4 2016

GMED Guru Trades in Q4 2016

Mario Gabelli 19,900 sh (New)
Steven Cohen 414,380 sh (New)
Joel Greenblatt 157,283 sh (-78.52%)
Paul Tudor Jones 11,200 sh (-86.68%)
» More
Q1 2017

GMED Guru Trades in Q1 2017

Steven Cohen 388,700 sh (-6.20%)
Paul Tudor Jones 8,900 sh (-20.54%)
Mario Gabelli 15,500 sh (-22.11%)
Joel Greenblatt 60,521 sh (-61.52%)
» More
Q2 2017

GMED Guru Trades in Q2 2017

Jim Simons 70,400 sh (New)
Paul Tudor Jones 17,651 sh (+98.33%)
Joel Greenblatt 75,721 sh (+25.12%)
Mario Gabelli 15,500 sh (unchged)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with GMED

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-06-30 Add 25.12%0.01%$29.12 - $33.95 $ 29.40-6%75,721
Joel Greenblatt 2017-03-31 Reduce -61.52%0.03%$24.79 - $29.96 $ 29.408%60,521
Mario Gabelli 2017-03-31 Reduce -22.11%$24.79 - $29.96 $ 29.408%15,500
Joel Greenblatt 2016-12-31 Reduce -78.52%0.17%$20.65 - $24.84 $ 29.4029%157,283
Mario Gabelli 2016-12-31 New Buy$20.65 - $24.84 $ 29.4029%19,900
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NAS:NUVA, NAS:WMGI, NYSE:PEN, NYSE:NVRO, SZSE:002223, OCSE:AMBU B, HKSE:01066, XSWX:TECN, NAS:LIVN, TSE:8086, SZSE:300529, NAS:INGN, OCSE:OSSR, XSWX:YPSN, TSE:6849, TSE:7575, NAS:IART, OSTO:EKTA B, NAS:SPNC, NYSE:ITGR » details
Traded in other countries:GM0N.Germany,
Headquarter Location:USA
Globus Medical Inc is a medical device company. It operates under two divisions that include innovative fusion and disruptive technology developing products for patients with musculoskeletal disorders for various treatment.

Globus Medical is a medical device company that develops products for patients with musculoskeletal disorders. The firm's products are organized into two categories: innovative fusion and disruptive technologies. The innovative fusion products include fusion products that treat a variety of spinal disorders and can be used in several surgical applications. The disruptive technology products are used for applications such as minimally invasive surgery and new treatment alternatives, including motion preservation and regenerative biologic technologies. Globus Medical generates the vast majority of its revenue in the United States.

Top Ranked Articles about Globus Medical Inc

Globus Medical Schedules Third Quarter 2017 Earnings Release and Conference Call
Globus Medical Announces First Spine Surgeries Using ExcelsiusGPS™
Globus Medical Announces First Case in Orthopedic Trauma
Globus Medical Appoints David M. Demski as CEO
Globus Medical Announces Acquisition of Robotics Developer KB Medical
Globus Medical Schedules Second Quarter 2017 Earnings Release and Conference Call
Globus Medical Schedules First Quarter 2017 Earnings Release and Conference Call
Globus Medical to Present at Leerink Partners 6th Annual Global Healthcare Conference 2017
AUDUBON, Pa., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:NYSE:GMED), a leading musculoskeletal implant manufacturer, today announced that management will present at the Leerink Partners 6th Annual Global Healthcare Conference at the Lotte New York Palace Hotel in New York, New York on Wednesday, February 15, 2017 at 9:30 a.m. ET.
A live webcast of the presentation will be available on the Investor Relations page of the Globus Medical website at www.globusmedical.com/investors.  A replay of the presentation will remain available on the website for 30 days after the live webcast.About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal implant company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at www.globusmedical.com.Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms.  These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends.  Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted.  These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks.  For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission.  These documents are available at www.sec.gov.  Moreover, we operate in an evolving environment.  New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.  Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements.  Forward-looking statements contained in this press release speak only as of the date of this press release.  We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.
Contact:
Dan Scavilla
Senior Vice President and Chief Financial Officer
Phone: (610) 930-1800
Email: [email protected]
www.globusmedical.com

Read more...
Globus Medical Schedules Fourth Quarter and Full Year 2016 Earnings Release and Conference Call

AUDUBON, Pa., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:NYSE:GMED), a leading musculoskeletal implant manufacturer, will announce its financial results for the fourth quarter and full year ended December 31, 2016 after the market close on Monday, February 27, 2017. A copy of the release will be available on the Globus Medical website at www.globusmedical.com/investors.
Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 5:30 p.m. Eastern Time. Globus invites all interested parties to join the call by dialing: 1-855-533-7141 United States Participants
1-720-545-0060 International Participants There is no passcode for the teleconference. For interested parties who do not wish to ask questions, the teleconference will be webcast live and may be accessed through a link on the Globus Medical website at www.globusmedical.com/investors.  The call will be archived until Monday, March 6, 2017. The audio archive can be accessed by calling 1-855-859-2056 in the U.S. or 1-404-537-3406 from outside the U.S. The passcode for the audio replay is 6940-2658. About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal implant company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at www.globusmedical.com. 
Contact:
Dan Scavilla
Senior Vice President and Chief Financial Officer
Phone: (610) 930-1800
Email: [email protected]
www.globusmedical.com

Read more...

Ratios

vs
industry
vs
history
PE Ratio 26.46
GMED's PE Ratio is ranked higher than
54% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 30.77 vs. GMED: 26.46 )
Ranked among companies with meaningful PE Ratio only.
GMED' s PE Ratio Range Over the Past 10 Years
Min: 12.96  Med: 24.23 Max: 35.64
Current: 26.46
12.96
35.64
Forward PE Ratio 20.88
GMED's Forward PE Ratio is ranked higher than
73% of the 55 Companies
in the Global Medical Devices industry.

( Industry Median: 25.06 vs. GMED: 20.88 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 26.46
GMED's PE Ratio without NRI is ranked higher than
52% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 27.81 vs. GMED: 26.46 )
Ranked among companies with meaningful PE Ratio without NRI only.
GMED' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.96  Med: 24.23 Max: 35.64
Current: 26.46
12.96
35.64
Price-to-Owner-Earnings 26.84
GMED's Price-to-Owner-Earnings is ranked higher than
62% of the 106 Companies
in the Global Medical Devices industry.

( Industry Median: 37.10 vs. GMED: 26.84 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
GMED' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 17.67  Med: 26.48 Max: 71.82
Current: 26.84
17.67
71.82
PB Ratio 3.88
GMED's PB Ratio is ranked lower than
61% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. GMED: 3.88 )
Ranked among companies with meaningful PB Ratio only.
GMED' s PB Ratio Range Over the Past 10 Years
Min: 2.45  Med: 3.62 Max: 4.94
Current: 3.88
2.45
4.94
PS Ratio 4.78
GMED's PS Ratio is ranked lower than
67% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. GMED: 4.78 )
Ranked among companies with meaningful PS Ratio only.
GMED' s PS Ratio Range Over the Past 10 Years
Min: 2.48  Med: 4.35 Max: 5.62
Current: 4.78
2.48
5.62
Price-to-Free-Cash-Flow 22.49
GMED's Price-to-Free-Cash-Flow is ranked higher than
62% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 28.08 vs. GMED: 22.49 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GMED' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 16.11  Med: 26.92 Max: 75.46
Current: 22.49
16.11
75.46
Price-to-Operating-Cash-Flow 16.49
GMED's Price-to-Operating-Cash-Flow is ranked higher than
60% of the 138 Companies
in the Global Medical Devices industry.

( Industry Median: 19.79 vs. GMED: 16.49 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GMED' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 12.28  Med: 19.47 Max: 32.2
Current: 16.49
12.28
32.2
EV-to-EBIT 16.65
GMED's EV-to-EBIT is ranked higher than
65% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 23.37 vs. GMED: 16.65 )
Ranked among companies with meaningful EV-to-EBIT only.
GMED' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.7  Med: 14.5 Max: 21.3
Current: 16.65
6.7
21.3
EV-to-EBITDA 12.68
GMED's EV-to-EBITDA is ranked higher than
61% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 17.75 vs. GMED: 12.68 )
Ranked among companies with meaningful EV-to-EBITDA only.
GMED' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.7  Med: 12.2 Max: 17.9
Current: 12.68
5.7
17.9
EV-to-Revenue 4.22
GMED's EV-to-Revenue is ranked lower than
58% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. GMED: 4.22 )
Ranked among companies with meaningful EV-to-Revenue only.
GMED' s EV-to-Revenue Range Over the Past 10 Years
Min: 2  Med: 3.8 Max: 5.1
Current: 4.22
2
5.1
PEG Ratio 2.39
GMED's PEG Ratio is ranked lower than
52% of the 77 Companies
in the Global Medical Devices industry.

( Industry Median: 2.45 vs. GMED: 2.39 )
Ranked among companies with meaningful PEG Ratio only.
GMED' s PEG Ratio Range Over the Past 10 Years
Min: 1.39  Med: 2.24 Max: 2.59
Current: 2.39
1.39
2.59
Current Ratio 7.75
GMED's Current Ratio is ranked higher than
90% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.67 vs. GMED: 7.75 )
Ranked among companies with meaningful Current Ratio only.
GMED' s Current Ratio Range Over the Past 10 Years
Min: 4.88  Med: 7.08 Max: 10.12
Current: 7.75
4.88
10.12
Quick Ratio 6.14
GMED's Quick Ratio is ranked higher than
89% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. GMED: 6.14 )
Ranked among companies with meaningful Quick Ratio only.
GMED' s Quick Ratio Range Over the Past 10 Years
Min: 3.82  Med: 5.6 Max: 8.29
Current: 6.14
3.82
8.29
Days Inventory 283.77
GMED's Days Inventory is ranked lower than
83% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 139.39 vs. GMED: 283.77 )
Ranked among companies with meaningful Days Inventory only.
GMED' s Days Inventory Range Over the Past 10 Years
Min: 125.66  Med: 265.97 Max: 295.28
Current: 283.77
125.66
295.28
Days Sales Outstanding 58.53
GMED's Days Sales Outstanding is ranked higher than
66% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 67.97 vs. GMED: 58.53 )
Ranked among companies with meaningful Days Sales Outstanding only.
GMED' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.59  Med: 52.25 Max: 59.53
Current: 58.53
50.59
59.53
Days Payable 41.51
GMED's Days Payable is ranked lower than
67% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. GMED: 41.51 )
Ranked among companies with meaningful Days Payable only.
GMED' s Days Payable Range Over the Past 10 Years
Min: 28.24  Med: 45.7 Max: 52.41
Current: 41.51
28.24
52.41

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.90
GMED's 3-Year Average Share Buyback Ratio is ranked higher than
74% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: -4.90 vs. GMED: -0.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GMED' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.6  Med: -1.2 Max: -0.8
Current: -0.9
-1.6
-0.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 15.89
GMED's Price-to-Net-Cash is ranked lower than
58% of the 105 Companies
in the Global Medical Devices industry.

( Industry Median: 14.17 vs. GMED: 15.89 )
Ranked among companies with meaningful Price-to-Net-Cash only.
GMED' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 6.32  Med: 13 Max: 31.3
Current: 15.89
6.32
31.3
Price-to-Net-Current-Asset-Value 7.92
GMED's Price-to-Net-Current-Asset-Value is ranked lower than
55% of the 210 Companies
in the Global Medical Devices industry.

( Industry Median: 7.13 vs. GMED: 7.92 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
GMED' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.2  Med: 5.83 Max: 8.94
Current: 7.92
3.2
8.94
Price-to-Tangible-Book 5.03
GMED's Price-to-Tangible-Book is ranked lower than
55% of the 274 Companies
in the Global Medical Devices industry.

( Industry Median: 4.11 vs. GMED: 5.03 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GMED' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.65  Med: 4 Max: 5.67
Current: 5.03
2.65
5.67
Price-to-Intrinsic-Value-Projected-FCF 1.63
GMED's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
70% of the 130 Companies
in the Global Medical Devices industry.

( Industry Median: 2.26 vs. GMED: 1.63 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
GMED' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.49  Med: 1.71 Max: 1.84
Current: 1.63
1.49
1.84
Price-to-Median-PS-Value 1.10
GMED's Price-to-Median-PS-Value is ranked lower than
56% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 1.05 vs. GMED: 1.10 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GMED' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.58  Med: 1 Max: 1.31
Current: 1.1
0.58
1.31
Price-to-Peter-Lynch-Fair-Value 2.24
GMED's Price-to-Peter-Lynch-Fair-Value is ranked lower than
59% of the 51 Companies
in the Global Medical Devices industry.

( Industry Median: 2.11 vs. GMED: 2.24 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
GMED' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.48  Med: 2.21 Max: 2.53
Current: 2.24
1.48
2.53
Price-to-Graham-Number 2.43
GMED's Price-to-Graham-Number is ranked lower than
51% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. GMED: 2.43 )
Ranked among companies with meaningful Price-to-Graham-Number only.
GMED' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.24  Med: 2.12 Max: 2.96
Current: 2.43
1.24
2.96
Earnings Yield (Greenblatt) % 5.99
GMED's Earnings Yield (Greenblatt) % is ranked higher than
81% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.94 vs. GMED: 5.99 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GMED' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.7  Med: 6.9 Max: 15
Current: 5.99
4.7
15
Forward Rate of Return (Yacktman) % 14.69
GMED's Forward Rate of Return (Yacktman) % is ranked higher than
67% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 6.44 vs. GMED: 14.69 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
GMED' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 14  Med: 14.5 Max: 16
Current: 14.69
14
16

More Statistics

Revenue (TTM) (Mil) $595.44
EPS (TTM) $ 1.11
Beta0.99
Short Percentage of Float14.06%
52-Week Range $19.25 - 34.03
Shares Outstanding (Mil)96.29

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 625 687 756 781
EPS ($) 1.26 1.40 1.59 1.63
EPS without NRI ($) 1.26 1.40 1.59 1.63
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.40%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}